<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00581009</url>
  </required_header>
  <id_info>
    <org_study_id>HS#2001-1616</org_study_id>
    <nct_id>NCT00581009</nct_id>
  </id_info>
  <brief_title>The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients</brief_title>
  <official_title>The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of sleep deprivation treatment in accelerating
      antidepressant responses when administered during the first week of medications and
      augmenting a sustained response with chronobiological interventions. Sleep deprivation and
      chronobiological augmentation may offer a rapid and sustained antidepressant response in mood
      disorder patients treated with medication, sleep deprivation, bright light therapy and sleep
      phase advance compared with medication only. The chronobiological treatment is rapid,
      non-invasive and has few side effects and could be of significant clinical benefit.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2001</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Rating Score for Depression</measure>
    <time_frame>within the first seven weeks (plus or minus 1 day) after sleep deprivation and chronobiological therapy</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chronobiological augmentation group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>medication only group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDD Mechanism</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>chronobiological augmentation</intervention_name>
    <description>Sleep deprivation for one night, Chronobiological augmentation consists of partial sleep phase advance for three nights and Light therapy for two hours for three days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sertraline, lithium</intervention_name>
    <description>Antidepressant, Subjects will be started on a serotonin specific reuptake inhibitor (SSRI), sertraline 100 mg (50mg hs x 2) daily or other SSRI's such as Paxil 20 mg or Prozac 20 mg daily and continue treatment for seven weeks.
Mood stabilizer, subjects will be treated with lithium 450 mg twice a day or another mood stabilizer such as depakote or valproate and continue treatment for seven weeks.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Zoloft</other_name>
    <other_name>Lithium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>one night of sleep deprivation and two FDG PET scans</intervention_name>
    <description>MDD Mechanism Only depressed subjects will have two FDG PET scans consisting of a baseline FDG PET scan and a sleep deprived FDG PET scan. One night of regular sleep,one night of sleep deprivation and one night of recovery sleep for a total of four nights at a sleep laboratory facility.</description>
    <arm_group_label>MDD Mechanism</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria include:

          1. Subjects must be English speaking

          2. Subjects must have either bipolar or unipolar depression diagnosis or be a normal
             control.

          3. Subjects must be between : 18 to 75

        Non-English speaking subjects will be excluded since scales for measuring depression have
        not been validated in languages other than English.

        Exclusion Criteria:

        Exclusion criteria include:

          1. Suicidality, or psychosis

          2. Unstable medical conditions

          3. Epilepsy, serious head injury, or other significant neurological disorders

          4. Dementia, mental retardation (moderate or severe), coma

          5. Prior exposure to radiation which might cause the subject to exceed standard
             guidelines

          6. Substance abuse or alcoholism in the past six months

          7. Unreliability or inability to adhere to the requirements of the study

          8. Irregular sleep-wake schedules (nightshift, jet lag)

          9. Use of CNS medications which may affect sleep or functional brain imaging (i.e., use
             of sleeping pills, antidepressants or other mood stabilizers or other medications
             which may affect the sleep EEG)

         10. Sleep apnea, periodic limb movements of sleep, narcolepsy, circadian sleep phase
             disorders

         11. Donation or loss of blood (&gt;400 ml) within the past month

         12. Current or very recent intercurrent illnesses, painful conditions or other disorders,
             which in the judgement of the investigators, might invalidate the scientific goals of
             the study or pose undesirable difficulties or risks for the subject.

         13. Hamilton Rating Scale of Depression (HRSD-17 items)&lt;17 unless subject is a normal
             control subject.

         14. Pregnancy or breast feeding

         15. Individuals who would be unable to undergo a magnetic resonance imaging (MRI) scan,
             for example, individuals who suffer from claustrophobia, or who have metal clips in
             their body.

         16. Unable to cease taking psychoactive medications which are not part of this protocol
             (2-5 weeks) prior to PET scans.

         17. Patients with previous history of significant adverse reactions to sertraline or
             sertraline-like drugs or other SSRI's such as Paxil or Prozac

         18. Subjects with diagnosis of eating disorder/bulimia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry F Chaitin, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph C Wu, M.D.</last_name>
    <phone>949-824-7867</phone>
    <email>jcwu@uci.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph C Wu, M.D.</last_name>
      <phone>949-824-7867</phone>
      <email>jcwu@uci.edu</email>
    </contact>
    <investigator>
      <last_name>William E Bunney, Jr., M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Potkin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jody Rawles, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Nguyen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marquis Vawter, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcel Hungs, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093 - 0603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John R Kelsoe, M.D.</last_name>
      <phone>858-534-5927</phone>
      <email>jkelsoe@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>John R Kelsoe, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2007</study_first_posted>
  <last_update_submitted>November 1, 2010</last_update_submitted>
  <last_update_submitted_qc>November 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Joseph C. Wu, M. D. ,Associate Professor, Psychiatry, UCI-SOM, Clinical Director, Brain Imaging Center</name_title>
    <organization>University of California, Irvine</organization>
  </responsible_party>
  <keyword>Sleep deprivation</keyword>
  <keyword>antidepressant</keyword>
  <keyword>depression</keyword>
  <keyword>chronobiological</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Sleep Deprivation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Dopamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

